Simple Plex Control for Human CD40/TNFRSF5

Name: Simple Plex Control for Human CD40/TNFRSF5
Brand: R&D Systems
SKU: 898323
Price: 150 USD
Availability: InStock

R&D Systems | Catalog # 898323

Submit a review

Citations

Product Documents

Control for use with Human CD40/TNFRSF5 Simple Plex Cartridge Kit

Product Summary
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species

Human

Applications

Control, Simple Plex Automated Immunoassay

Product Summary for Simple Plex Control for Human CD40/TNFRSF5

INTENDED USE AND DESCRIPTION: For use a quantitative control for the determination of human CD40/TNFRSF5 concentrations in biological fluids. Controls are supplied lyophilized. Please refer to the lot specific certificate of analysis and Simple Plex Lyophilized Quality Control product insert for additional information.

Formulation, Preparation, and Storage

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Storage

• Store lyophilized controls at 2-8 °C. Lyophilized controls are stable for up to 12 months from date of receipt.
• Reconstituted controls are stable for up to 6 months from date of preparation when stored at ≤ -70 °C. Storage at -20° C is not recommended.
• Individual frozen aliquots of low and high controls are designed as single-use entities. Thaw directly before use and discard any remaining volume.

Background: CD40/TNFRSF5

CD40, also known as TNFRSF5, is a transmembrane TNF superfamily receptor that is expressed on the surface of B cells, dendritic cells, macrophages, monocytes and platelets, as well as endothelial and epithelial cells. Interaction of CD40 with CD40 Ligand leads to the aggregation of CD40 molecules resulting in the initiation of bidirectional intracellular signaling in both CD40 and CD40 Ligand expressing cells. This interaction promotes B cell activation and T cell-dependent humoral responses. CD40 serves multiple functions in both hematopoietic and epithelial cancers and is a target for tumor immunotherapy. Dysregulation of CD40/CD40 Ligand expression and interactions contributes to disease severity in AIDS, atherosclerosis, atherothrombosis, and restenosis.